Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Current Deferred Revenue (2016 - 2018)

Catalyst Pharmaceuticals (CPRX) has disclosed Current Deferred Revenue for 7 consecutive years, with $33408.0 as the latest value for Q4 2018.

  • For the quarter ending Q4 2018, Current Deferred Revenue rose 39.14% year-over-year to $33408.0, compared with a TTM value of $33408.0 through Dec 2018, up 39.14%, and an annual FY2018 reading of $33408.0, up 39.14% over the prior year.
  • Current Deferred Revenue was $33408.0 for Q4 2018 at Catalyst Pharmaceuticals, up from $21914.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $33408.0 in Q4 2018 and bottomed at $3254.0 in Q1 2014.
  • Average Current Deferred Revenue over 5 years is $16062.2, with a median of $18711.0 recorded in 2016.
  • The sharpest move saw Current Deferred Revenue skyrocketed 323.72% in 2015, then fell 2.27% in 2018.
  • Year by year, Current Deferred Revenue stood at $4158.0 in 2014, then surged by 335.14% to $18093.0 in 2015, then rose by 0.01% to $18094.0 in 2016, then skyrocketed by 32.7% to $24011.0 in 2017, then soared by 39.14% to $33408.0 in 2018.
  • Business Quant data shows Current Deferred Revenue for CPRX at $33408.0 in Q4 2018, $21914.0 in Q3 2018, and $27184.0 in Q2 2018.